In this article, we will look at the 12 Oversold Growth Stocks to Buy According to Analysts.
On September 27, Wharton professor emeritus and WisdomTree senior economist Jeremy Siegel joined CNBC for an interview to discuss the latest PCE report and what the data reveal about the market. He sees the latest economic data as positive for the stock market. The inflation report was in line with expectations, with no upside surprises and year-over-year inflation at 2.9%. Although the inflation is still above the Federal Reserve’s target, Siegel calls it tame inflation based on the month-over-month numbers.
Siegel highlighted that the Fed should look past inflation pushed up by tariffs, which act like a tax. Tariffs raise prices but don’t indicate strong demand for goods. He suggests that the Fed should focus on underlying inflation driven by real demand, rather than tariff effects.
He also highlights recent strong economic indicators, like a lower trade deficit and durable goods orders. These factors have led forecasters to raise GDP growth estimates for the third quarter. Despite a weak first quarter, the economy is showing decent growth in the mid to high single-digit range, which is positive though not excessive. Siegel views the upcoming fourth quarter as a key test to see how tariffs truly affect consumer spending, especially during the holiday season.
With that, let’s take a look at the 12 Oversold Growth Stocks to Buy According to Analysts.
Our Methodology
To compile the list of 12 Oversold Growth Stocks to Buy According to Analysts, we used the Finviz Stock Screener, CNN, and Insider Monkey’s Q2 hedge funds database as our sources. Using the Screener, we aggregated a list of growth stocks that have declined more than 30% on a year-to-date basis, but analysts expect more than 30% upside. Next, we cross-checked the decline and upside from CNN and ranked the stocks in ascending order of the analyst upside potential. We have also added the hedge fund sentiment around each stock. Please note that the data was recorded on September 26, 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
12 Oversold Growth Stocks to Buy According to Analysts
12. EPAM Systems, Inc. (NYSE:EPAM)
Year-to-Date Performance: -34.55%
Number of Hedge Fund Holders: 48
Analyst Upside Potential: 41.68%
EPAM Systems, Inc. (NYSE:EPAM) is one of the Oversold Growth Stocks to Buy According to Analysts. On September 12, EPAM Systems, Inc. (NYSE:EPAM) announced that The Reference, which is Belgium’s first digital agency, has now been rebranded as Empathy Lab.
This merges The Reference with the former Emakina Belgium team to result in Empathy Lab, which aims to lead in AI-driven, human-centered digital experiences across Europe. The Reference was founded in 1993 and has helped clients for over 3 decades with digital transformations. Now the Empathy Lab by EPAM Systems, Inc. (NYSE:EPAM) brings together data scientists, AI experts, strategists, and creatives. Some of the key features include AI-powered marketing, commerce, and customer engagement solutions that generate real business growth.
EPAM Systems, Inc. (NYSE:EPAM) is a global company that provides digital engineering and transformation services. It helps businesses use AI, cloud, and advanced technologies to improve customer experiences and drive growth.
11. SPS Commerce, Inc. (NASDAQ:SPSC)
Year-to-Date Performance: -42.59%
Number of Hedge Fund Holders: 34
Analyst Upside Potential: 42.93%
SPS Commerce, Inc. (NASDAQ:SPSC) is one of the Oversold Growth Stocks to Buy According to Analysts. On September 23, George Kurosawa from Citi reduced the firm’s price target on SPS Commerce, Inc. (NASDAQ:SPSC) from $173 to $166, while reiterating a Buy rating on the stock.
The analyst highlighted the company’s strong position as a leader in the retail supply chain network. He noted that this gives the company access to a larger total addressable market, which supports sustainable growth.
Moreover, SPS Commerce, Inc. (NASDAQ:SPSC) also uses network data to improve its sales targeting. Kurosawa believes that this approach is expected to help with revenue recovery and also increase cross-selling opportunities. The analyst noted the company’s efforts in relationship management, which have improved lately as a result of recent acquisitions. He believes that this is expected to lead to more conversations and upselling with customers.
The analyst reduced the price target on concerns of slower growth in large customers. He expects the company to achieve a 2-point annual expansion in EBITDA margin, with high single-digit revenue growth.
SPS Commerce, Inc. (NASDAQ:SPSC) provides cloud-based supply chain solutions that connect retail partners worldwide to improve their operations.
10. OneStream, Inc. (NASDAQ:OS)
Year-to-Date Performance: -31.03%
Number of Hedge Fund Holders: 32
Analyst Upside Potential: 43.66%
OneStream, Inc. (NASDAQ:OS) is one of the Oversold Growth Stocks to Buy According to Analysts. On September 19, Chris Quintero from Morgan Stanley reiterated a Buy rating on OneStream, Inc. (NASDAQ:OS) with a $27 price target.
The analyst noted that they see a strong probability of positive earnings estimate revisions for the company over the next two quarters. This is expected to drive expansion in the company’s valuation.
OneStream, Inc. (NASDAQ:OS) topped Wall Street estimates during the fiscal second quarter of 2025. It posted a revenue of $147.59 million, reflecting a 25.61% year-over-year growth and ahead of expectations by $6.49 million. The EPS of $0.05 also topped estimates by $0.04.
In addition to Morgan Stanley, on September 16, John Blackledge from TD Cowen also reiterated a Buy rating on the stock with a price target of $28.
OneStream, Inc. (NASDAQ:OS) provides the Digital Finance Cloud, a unified, AI-enabled software platform designed for the office of the CFO.
9. Atlassian Corporation (NASDAQ:TEAM)
Year-to-Date Performance: -32.99%
Number of Hedge Fund Holders: 64
Analyst Upside Potential: 50.84%
Atlassian Corporation (NASDAQ:TEAM) is one of the Oversold Growth Stocks to Buy According to Analysts. On September 23, Koji Ikeda from Bank of America Securities initiated coverage of Atlassian Corporation (NASDAQ:TEAM) with a Hold rating and $200 price target.
The analyst notes that the company has a strong position as a centralized planning tool with over 300,000 customers. He sees Atlassian Corporation (NASDAQ:TEAM) to be well-positioned to capture a large share of the $58 billion collaboration and project management market.
In addition, Ikeda also remains positive about the company’s long-term growth and free cash flow potential. However, the analyst remains neutral on the stock because he believes that accelerating the end of sales and support for its Data Center offering and two large acquisitions can make it difficult for the company to justify its long-term growth prospects. Under the current circumstances, Ikeda sees the company’s risk/reward profile as neutral.
Atlassian Corporation (NASDAQ:TEAM) is a technology company that creates tools for team collaboration and project management.
8. Intapp, Inc. (NASDAQ:INTA)
Year-to-Date Performance: -34.97%
Number of Hedge Fund Holders: 28
Analyst Upside Potential: 52.27%
Intapp, Inc. (NASDAQ:INTA) is one of the Oversold Growth Stocks to Buy According to Analysts. On September 16, Intapp, Inc. (NASDAQ:INTA) announced that Infinedi Partners has chosen Intapp DealCloud to manage its deal pipeline, relationships, and business development.
Infinedi Partners is a private equity firm that is focused on long-term investments in intelligence industry businesses. The adoption of DealCloud strategically aligns with Infinedi’s strategy to use agile technology to support growth. This is because the platform will help the firm handle deal flow at scale, improve operational processes, and boost productivity through AI-driven tools. Moreover, the AI and automation in the platform will reduce manual work like data entry and provide real-time insights on investment trends and relationships.
Intapp, Inc. (NASDAQ:INTA) provides AI-powered software solutions for advisory, capital markets, and legal firms.
7. Alkami Technology, Inc. (NASDAQ:ALKT)
Year-to-Date Performance: -31.38%
Number of Hedge Fund Holders: 20
Analyst Upside Potential: 57.98%
Alkami Technology, Inc. (NASDAQ:ALKT) is one of the Oversold Growth Stocks to Buy According to Analysts. On September 23, Alkami Technology, Inc. (NASDAQ:ALKT) announced expanding its partnership with Red Rocks Credit Union. The partnership expanded when Red Rocks Credit Union added the company’s Digital Banking Solution and Data & Marketing Solution to its existing Onboarding & Account Opening Solution.
Red Rocks has been serving Colorado communities for over 40 years with the aim of providing a personalized and trustworthy digital banking experience. The expanded tech suite of Alkami Technology, Inc. (NASDAQ:ALKT) will enable Red Rocks to enhance online and mobile banking for retail and business members with consistent, intuitive interfaces and additional business banking features.
Alkami Technology, Inc. (NASDAQ:ALKT) is a cloud-based digital banking platform provider for financial institutions in the United States.
6. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Year-to-Date Performance: -32.99%
Number of Hedge Fund Holders: 44
Analyst Upside Potential: 71.02%
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the Oversold Growth Stocks to Buy According to Analysts. Wall Street has a mixed opinion on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) since the company released its fiscal second quarter 2025 results.
The company posted $178.49 million in revenue, down 10.61% year-over-year and below expectations by $10.15 million. On the bright side, the EPS of negative $0.33 topped estimates by $0.15. Management noted that they are proud of the FDA approval of EMPAVELI for two rare kidney diseases, including C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis. This is because the approval marked the first FDA-approved treatment for these conditions in patients aged 12 and older.
Despite this, Wall Street has a mixed opinion about Apellis Pharmaceuticals, Inc. (NASDAQ:APLS). Earlier on August 6, Tazeen Ahmad from Band of America Securities reiterated a Hold rating on the stock with a $26 price target. The analyst acknowledged the FDA approval of EMPAVELI as a key milestone. However, he noted that the market is fragmented with payor access challenges that may slow the drug’s launch. He added that the patient group is small and possibly underdiagnosed, limiting broad uptake. Moreover, the physician’s choice between Empaveli and competitors like Fabhalta adds uncertainty to its adoption.
More recently, on September 7, Steven Seedhouse from Cantor Fitzgerald reiterated a Buy rating on the stock with a $40 price target.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) develops and commercializes therapies that target the complement system to treat diseases with unmet medical needs.
5. Clearwater Analytics Holdings, Inc. (NYSE:CWAN)
Year-to-Date Performance: -33.96%
Number of Hedge Fund Holders: 51
Analyst Upside Potential: 75.29%
Clearwater Analytics Holdings, Inc. (NYSE:CWAN) is one of the Oversold Growth Stocks to Buy According to Analysts. On September 17, Clearwater Analytics Holdings, Inc. (NYSE:CWAN) announced new features in its Alternative Assets Solution at Connect ’25, aimed at helping institutional investors manage private credit more efficiently.
The new solutions directly address the scalability and compliance challenges faced by the $2.5 trillion private credit market. The updates automate complex loan calculations and integrate these with accounting workflows, thereby reducing manual work on accruals and cash flows.
Moreover, the solution also uses AI to speed up fund research and due diligence, cutting review times from weeks to days. It syncs data in real-time between asset owners and managers, ensuring accuracy with one source of truth. President of Clearwater Analytics Holdings, Inc. (NYSE:CWAN), Kirat Singh, noted that private credit is now a major part of portfolios, but operational systems lag behind. These enhancements help firms increase allocations without raising operational risk.
Clearwater Analytics Holdings, Inc. (NYSE:CWAN) provides a cloud-native platform for institutional investors to manage investments across global public and private markets.
4. Chime Financial, Inc. (NASDAQ:CHYM)
Year-to-Date Performance: -41.90%
Number of Hedge Fund Holders: 46
Analyst Upside Potential: 76.25%
Chime Financial, Inc. (NASDAQ:CHYM) is one of the Oversold Growth Stocks to Buy According to Analysts. Wall Street is bullish on Chime Financial, Inc. (NASDAQ:CHYM) after the company topped estimates for its inaugural quarter as a publicly listed company.
The company delivered $528.15 million in revenue, which topped estimates by $25.36 million. Moreover, the EPS of $0.12 also topped estimates by $5.05. Management also provided future guidance and is expecting third-quarter revenue between $525 million and $535 million, reflecting between 24% and 27% growth. Whereas the full-year revenue is expected to be between $2.135 billion and $2.155 billion, reflecting between 28% and 29% growth.
Several analysts have reiterated their bullish sentiment. For instance, on September 11, James Faucette from Morgan Stanley reiterated a Buy rating on Chime Financial, Inc. (NASDAQ:CHYM) with a price target of $40. More recently, on September 14, Jeff Cantwell from Seaport Global also reiterated a Buy rating on the stock, while raising the price target from $37 to $42.
Chime Financial, Inc. (NASDAQ:CHYM) is a fintech company that provides banking services through FDIC-insured bank partners.
3. Telix Pharmaceuticals Limited (NASDAQ:TLX)
Year-to-Date Performance: -32.60%
Number of Hedge Fund Holders: 1
Analyst Upside Potential: 80.77%
Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the Oversold Growth Stocks to Buy According to Analysts. On September 23, Telix Pharmaceuticals Limited (NASDAQ:TLX) announced that the US Centers for Medicare & Medicaid Services had granted Transitional Pass-Through payment status for Gozellix. Gozellix is the company’s next-generation PSMA-PET imaging agent for prostate cancer.
The Transitional Pass-Through payment status means that hospitals will get separate reimbursement for using Gozellix starting October 1, 2025. Gozellix is a kit used to prepare gallium-68 Gozetotide for PET scans that helps detect PSMA-positive lesions in men with prostate cancer, especially those suspected of metastasis or biochemical recurrence.
Moreover, it has also been assigned a permanent HCPCS Level II code A9616, allowing recognition by CMS and commercial insurers for reimbursement starting October 1, 2025.
Telix Pharmaceuticals Limited (NASDAQ:TLX) is a biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals.
2. Vaxcyte, Inc. (NASDAQ:PCVX)
Year-to-Date Performance: -61.42%
Number of Hedge Fund Holders: 44
Analyst Upside Potential: 260.92%
Vaxcyte, Inc. (NASDAQ:PCVX) is one of the Oversold Growth Stocks to Buy According to Analysts. On September 3, Vaxcyte, Inc. (NASDAQ:PCVX) announced progress in its VAX-31 infant vaccine study for Phase 2. The drug has moved to the third and final dose-finding study after protocol changes that added a new optimized dose arm and removed the low-dose arm, with about 900 infants to be enrolled.
It compares VAX-31 to the current standard vaccine, Prevnar 20, and the company expects key safety, tolerability, and immune response data by mid-2027. CEO of Vaxcyte, Inc. (NASDAQ:PCVX), Grant Pickering, emphasized that the Optimized Dose could prompt stronger immune responses. VAX-31 aims to cover about 92% of invasive pneumococcal disease and 93% of acute otitis media cases in US children under five.
Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage vaccine company focused on developing innovative conjugate and protein vaccines to prevent or treat bacterial infectious diseases.
1. Viking Therapeutics, Inc. (NASDAQ:VKTX)
Year-to-Date Performance: -38.98%
Number of Hedge Fund Holders: 43
Analyst Upside Potential: 298.57%
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the Oversold Growth Stocks to Buy According to Analysts. On September 22, Justin Zelin from BTIG reiterated a Buy rating on Viking Therapeutics, Inc. (NASDAQ:VKTX) with a price target of $125.
The analyst likes the company’s solid position in the obesity and metabolic disease market. He noted that recent acquisitions by big names such as Pfizer acquiring Metsera underscores the strategic importance of this sector. He highlighted that Viking Therapeutics, Inc. (NASDAQ:VKTX) stands out as one of the few independent companies with an advanced and mature product portfolio, which makes it an attractive partner or acquisition target.
The company’s competitive advantage comes from its differentiated programs. Notably, VK2735 offers potential for monthly dosing. The company also expects to file an IND for an amylin agonist by late 2025. These innovations boost Viking’s chances for good financing and partnership deals.
Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company focused on developing treatments for metabolic and endocrine disorders.
While we acknowledge the potential of VKTX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VKTX and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
